AVITA Medical, Inc. (NASDAQ:RCEL) CFO Acquires $12,150.00 in Stock

AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O’toole bought 1,000 shares of AVITA Medical stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $12.15 per share, with a total value of $12,150.00. Following the completion of the purchase, the chief financial officer now directly owns 12,000 shares in the company, valued at $145,800. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

AVITA Medical Stock Performance

Shares of RCEL stock opened at $12.60 on Friday. AVITA Medical, Inc. has a 1 year low of $6.29 and a 1 year high of $21.70. The business’s fifty day moving average is $12.00 and its 200-day moving average is $14.69. The stock has a market cap of $321.94 million, a PE ratio of -9.47 and a beta of 1.54.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RCEL. Bank of New York Mellon Corp lifted its holdings in AVITA Medical by 45.7% in the 1st quarter. Bank of New York Mellon Corp now owns 106,368 shares of the company’s stock valued at $902,000 after acquiring an additional 33,375 shares during the last quarter. Rhumbline Advisers lifted its stake in AVITA Medical by 23.3% during the first quarter. Rhumbline Advisers now owns 22,913 shares of the company’s stock valued at $194,000 after purchasing an additional 4,326 shares during the last quarter. Vanguard Group Inc. boosted its holdings in AVITA Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 1,276,977 shares of the company’s stock worth $10,830,000 after buying an additional 6,467 shares in the last quarter. Renaissance Technologies LLC acquired a new position in AVITA Medical in the first quarter worth approximately $1,826,000. Finally, Engineers Gate Manager LP bought a new position in shares of AVITA Medical in the first quarter valued at $100,000. Institutional investors own 29.88% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $26.00 target price on shares of AVITA Medical in a research note on Thursday, October 19th. Bank of America boosted their target price on shares of AVITA Medical from $18.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Finally, Piper Sandler reduced their target price on shares of AVITA Medical from $23.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, November 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.60.

AVITA Medical Company Profile

AVITA Medical, Inc operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.